Enorama Pharma AB (publ) (ERMA.ST)

SEK 2.95

(3.15%)

Operating Expenses Summary of Enorama Pharma AB (publ)

Enorama Pharma AB (publ)'s latest annual operating expenses in 2023 was 38.22 Million SEK , down -93.06% from previous year.
Enorama Pharma AB (publ)'s latest quarterly operating expenses in 2024 Q2 was 8.79 Million SEK , up 3.91% from previous quarter.
Enorama Pharma AB (publ) reported a annual operating expenses of 41.34 Million SEK in annual operating expenses 2022, up 42.22% from previous year.
Enorama Pharma AB (publ) reported a annual operating expenses of 29.07 Million SEK in annual operating expenses 2021, up 14.57% from previous year.
Enorama Pharma AB (publ) reported a quarterly operating expenses of 8.45 Million SEK for 2024 Q1, down -6.54% from previous quarter.
Enorama Pharma AB (publ) reported a quarterly operating expenses of 8.54 Million SEK for 2023 Q1, down -32.74% from previous quarter.

Annual Operating Expenses Chart of Enorama Pharma AB (publ) (2023 - 2014)

Historical Annual Operating Expenses of Enorama Pharma AB (publ) (2023 - 2014)

Year	Operating Expenses	Operating Expenses Growth
2023	38.22 Million SEK	-93.06%
2022	41.34 Million SEK	42.22%
2021	29.07 Million SEK	14.57%
2020	25.37 Million SEK	-23.82%
2019	33.31 Million SEK	21.25%
2018	27.47 Million SEK	189.85%
2017	9.47 Million SEK	23.53%
2016	7.67 Million SEK	1272.51%
2015	559.01 Thousand SEK	-58.51%
2014	1.34 Million SEK	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	8.79 Million SEK	3.91%
2024 Q1	8.45 Million SEK	-6.54%
2023 Q1	8.54 Million SEK	-32.74%
2023 Q3	11.52 Million SEK	30.77%
2023 Q2	8.81 Million SEK	3.15%
2023 FY	2.87 Million SEK	-93.06%
2023 Q4	9.05 Million SEK	-21.44%
2022 Q3	7.62 Million SEK	-30.98%
2022 Q4	12.69 Million SEK	66.53%
2022 FY	41.34 Million SEK	42.22%
2022 Q1	10.21 Million SEK	53.92%
2022 Q2	11.04 Million SEK	8.13%
2021 Q3	8.32 Million SEK	28.31%
2021 FY	29.07 Million SEK	14.57%
2021 Q4	6.63 Million SEK	-20.3%
2021 Q1	5.88 Million SEK	-46.25%
2021 Q2	6.49 Million SEK	10.28%
2020 FY	25.37 Million SEK	-23.82%
2020 Q2	4.22 Million SEK	-16.79%
2020 Q1	5.08 Million SEK	-71.45%
2020 Q3	5.11 Million SEK	21.1%
2020 Q4	10.94 Million SEK	113.89%
2019 Q3	7.03 Million SEK	32.82%
2019 Q4	17.79 Million SEK	152.99%
2019 FY	33.31 Million SEK	21.25%
2019 Q1	3.18 Million SEK	-84.22%
2019 Q2	5.29 Million SEK	66.25%
2018 Q2	3.48 Million SEK	316.51%
2018 FY	27.47 Million SEK	189.85%
2018 Q4	20.18 Million SEK	581.4%
2018 Q3	2.96 Million SEK	-14.91%
2018 Q1	836 Thousand SEK	-87.46%
2017 Q3	1.93 Million SEK	750.67%
2017 Q1	1.17 Million SEK	-76.75%
2017 Q2	-298 Thousand SEK	-125.47%
2017 FY	9.47 Million SEK	23.53%
2017 Q4	6.66 Million SEK	243.79%
2016 Q1	111 Thousand SEK	108.56%
2016 FY	7.67 Million SEK	1272.51%
2016 Q4	5.03 Million SEK	2196.91%
2016 Q3	-240 Thousand SEK	-108.78%
2016 Q2	2.73 Million SEK	2363.96%
2015 FY	559.01 Thousand SEK	-58.51%
2015 Q2	381 Thousand SEK	-37.95%
2015 Q3	302 Thousand SEK	-20.73%
2015 Q4	-1.29 Million SEK	-529.14%
2015 Q1	614 Thousand SEK	0.0%
2014 FY	1.34 Million SEK	0.0%

Peer Operating Expenses Comparison of Enorama Pharma AB (publ)

Name	Operating Expenses	Operating Expenses Difference
AcuCort AB	13.24 Million SEK	-188.52%
AlzeCure Pharma AB (publ)	38.26 Million SEK	0.094%
BioGaia AB (publ)	507.08 Million SEK	92.462%
Enzymatica AB (publ)	79.92 Million SEK	52.173%
Gabather AB (publ)	9.47 Million SEK	-303.483%
Klaria Pharma Holding AB (publ.)	14.88 Million SEK	-156.826%
Moberg Pharma AB (publ)	27.46 Million SEK	-39.191%
Nanexa AB (publ)	135.78 Million SEK	71.848%
Newbury Pharmaceuticals AB (publ)	30.11 Million SEK	-26.95%
ODI Pharma AB	-5.00 SEK	764520100.0%
Orexo AB (publ)	659.4 Million SEK	94.203%
Probi AB (publ)	208.93 Million SEK	81.704%
Swedencare AB (publ)	1.12 Billion SEK	96.611%
Swedish Orphan Biovitrum AB (publ)	9.39 Billion SEK	99.593%
Toleranzia AB	6.97 Million SEK	-448.279%
Vivesto AB	355.71 Million SEK	89.254%